Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • emc易倍官网入口Press Releases
    • Media Updates
    • Media Resources
    • emc易倍官网入口Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • emc易倍官网入口Annual Reports & Regulated Information
    • emc易倍官网入口Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • emc易倍官网入口Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  •         EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • United States
    • Brazil
    • Canada
    • Mexico
    • emc易倍官网入口 Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • emc易倍官网入口 Poland
    • Russia
    • emc易倍官网入口 Czech Republic
    • Switzerland
    • emc易倍官网入口 Austria
    • UAE & Gulf
    • emc易倍官网入口 Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • emc易倍官网入口Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • emc易倍官网入口Rare Disease
    • emc易倍官网入口Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • emc易倍官网入口Patients
    • People
    • Governance
    • emc易倍官网入口Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Newsroom – Subscribe to Ipsen News

emc易倍官网入口

IPN price

€162.70

 €2.50 (1.56%)

  • Media Resources
  • emc易倍官网入口Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • emc易倍官网入口Terms and Conditions
  • emc易倍官网入口Cookie Policy
  • emc易倍官网入口Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

emc易倍官网入口 Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?






2026-05-26 6:01:51